title: Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.affiliation: 2nd Prop. Department of Internal Medicine Medical School Aristotle University of Thessaloniki Hippocrates Hospital Thessaloniki Greece. vathyros@gmail.com.
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
mesh_terms: D000613:Aminobutyrates / Q000494:pharmacology / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004338:Drug Combinations; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D013318:Stroke Volume / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination